Latest Developments in Cell and Gene Therapy Manufacturing
Cell and gene therapies are rapidly emerging as one of the most transformative areas in modern medicine. These advanced therapies aim to treat or potentially cure diseases by modifying a patient’s genetic material or using engineered cells to target specific conditions. Treatments such as CAR-T therapies have already demonstrated remarkable success in treating certain cancers, signalling a new era in precision medicine.
As global demand for advanced therapies continues to grow, attention is turning toward emerging manufacturing hubs that can support large-scale production. India, known for its strong pharmaceutical manufacturing capabilities, is increasingly exploring opportunities in cell and gene therapy (CGT) manufacturing. With expanding biotech infrastructure, a skilled scientific workforce, and cost-efficient production capabilities, the country has the potential to play a larger role in this evolving sector.
What the Opportunity Involves
1. Building Advanced Biomanufacturing Infrastructure
Cell and gene therapies require highly specialized manufacturing facilities capable of handling living cells, viral vectors, and complex biological processes. In recent years, India has seen growing investments in advanced biomanufacturing infrastructure, including facilities designed for cell culture, viral vector production, and gene-editing technologies.
These developments could support both domestic innovation and global partnerships in the advanced therapies space.
2. Strengthening Research and Clinical Capabilities
India’s expanding biotechnology research ecosystem is contributing to early-stage development of cell and gene therapies. Academic institutions, biotechnology startups, and pharmaceutical companies are increasingly collaborating on research related to gene editing, immunotherapy, and regenerative medicine.
In parallel, improvements in clinical trial infrastructure may help accelerate the testing and development of advanced therapies within the country.
3. Leveraging Cost-Efficient Manufacturing
One of India’s long-standing advantages in the pharmaceutical sector is its ability to produce medicines at competitive costs. If applied successfully to advanced therapy manufacturing, this capability could make complex treatments more affordable and accessible, particularly in emerging markets where cost remains a major barrier.
Cost-efficient production could also attract international biotech companies seeking reliable contract development and manufacturing partners.
4. Policy and Ecosystem Support
Government initiatives aimed at strengthening biotechnology innovation, research funding, and advanced manufacturing are helping create a supportive environment for cell and gene therapy development. Efforts to improve regulatory processes, encourage biotech startups, and build specialized research centres may further accelerate growth in this field.
Why Cell and Gene Therapy Manufacturing Matters Now
The global pipeline for cell and gene therapies has expanded rapidly over the past decade, with hundreds of therapies currently in clinical development. These treatments hold promise for conditions that were previously considered difficult or impossible to treat, including certain genetic disorders, rare diseases, and cancers.
However, manufacturing these therapies remains complex and resource-intensive. As the number of approved treatments grows, the industry will require scalable manufacturing capacity to meet global demand. This need creates opportunities for countries with strong scientific talent, manufacturing expertise, and supportive innovation ecosystems.
India’s growing biotechnology sector may allow it to contribute to this emerging manufacturing landscape.
Potential Impact on India’s Biotech Landscape
Expansion of Advanced Biotech Capabilities
Investment in cell and gene therapy manufacturing could significantly enhance India’s capabilities in advanced biotechnology, positioning the country at the forefront of next-generation therapeutic development.
Growth of Biotech Startups and Research Collaboration
A stronger focus on advanced therapies may stimulate the growth of biotechnology startups and encourage greater collaboration between academia, research institutions, and industry partners.
Improved Access to Advanced Therapies
Developing domestic manufacturing capabilities may eventually help reduce the cost of cell and gene therapies, improving patient access in India and other emerging markets.
Conclusion
India’s pharmaceutical and biotechnology industries are undergoing a period of rapid transformation as the global healthcare landscape shifts toward more advanced and personalized treatments. The rise of cell and gene therapies presents an opportunity for the country to expand beyond traditional pharmaceutical manufacturing and build capabilities in next-generation therapeutics.
If supported by continued investment in infrastructure, research, and regulatory development, India could emerge as an important manufacturing hub for advanced therapies—contributing to both global innovation and broader patient access to life-changing treatments.
Other Articles
Specialty Pharma: The Next Strategic Pivot for Indian Companies
No Comment! Be the first one.